SpringWorks Therapeutics (SWTX) to Release Earnings on Tuesday

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) is set to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.58. The business had revenue of $59.73 million for the quarter, compared to analysts' expectations of $34.42 million. SpringWorks Therapeutics's revenue for the quarter was up 59732900.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.25) EPS. On average, analysts expect SpringWorks Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ:SWTX traded up $0.65 during mid-day trading on Tuesday, reaching $31.59. 666,463 shares of the company traded hands, compared to its average volume of 950,475. SpringWorks Therapeutics has a 52 week low of $18.00 and a 52 week high of $53.92. The company's 50 day moving average price is $33.92 and its 200-day moving average price is $37.67. The firm has a market cap of $2.35 billion, a PE ratio of -6.83 and a beta of 0.79.

Analyst Ratings Changes

A number of equities research analysts recently commented on SWTX shares. HC Wainwright reiterated a "buy" rating and issued a $76.00 target price on shares of SpringWorks Therapeutics in a research report on Wednesday, August 28th. JPMorgan Chase & Co. upped their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an "overweight" rating in a research note on Wednesday, September 4th. Finally, Wedbush reiterated an "outperform" rating and set a $77.00 price objective (up previously from $75.00) on shares of SpringWorks Therapeutics in a report on Wednesday, August 28th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $68.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.